Dabigatran Etexilate Mesylate

Reduction Of Risk Of Stroke And Systemic Embolism In Non-valvular Atrial Fibrillation: Dabigatran is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Treatment Of Deep Venous Thrombosis and Pulmonary Embolism: Dabigatran is indicated for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5-10 days.

Reduction In The Risk Of Recurrence Of Deep Venous Thrombosis And Pulmonary Embolism: Dabigatran is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in patients who have been previously treated.

Prophylaxis Of Deep Vein Thrombosis And Pulmonary Embolism Following Hip Replacement Surgery: Dabigatran is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in patients who have undergone hip replacement surgery.